참고문헌 (29)

1. Korean Statistical Information Service. Cause of Death Statistics. Available from https://kosis.kr/statHtml/statHtml.do?orgId101&tblIdDT_1B34E01&conn_pathI2. Accessed Nov 15, 2020. 

2. Korean Liver Cancer Association (KLCA). 2018 Korean liver cancer association-national cancer center Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20(7):1042-1113. 

   상세보기

3. Fitzmaurice C, Abate D, Abbasi N, et al; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol 2019;5(12):1749-68. 

   상세보기

4. The Korean Association for the Study of the Liver. White Paper on Liver Diseases in Korea. Available from https://www.kasl.org/bbs/index.html?codeency&page1&number55&modeview. Accessed February 22, 2021. 

5. European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908-43. 

   상세보기

6. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301-14. 

   상세보기

7. Khalaf N, Ying J, Mittal S, et al. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol 2017;15(2):273-81. 

   상세보기

8. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6(12):1418-24. 

   상세보기

9. Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology 2017;65(4):1237-48. 

   상세보기

10. Goossens N, Singal AG, King LY, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol 2017;8(6):e101. 

    상세보기

11. Kondili LA, Romano F, Rolli FR, et al. Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology 2017;66(6): 1814-25. 

    상세보기

12. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology 2018; 154(6):1706-18.e1. 

    상세보기

13. Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018;68(1):78-88. 

    상세보기

14. Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 2019;69(4):1599-613. 

15. Kim YA, Lee YR, Park J, et al. Socioeconomic burden of cancer in Korea from 2011 to 2015. Cancer Res Treat 2020;52(3):896-906. 

    상세보기

16. Kim L, Kim JA, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 2014;36:e2014008. 

17. Kim DW, Lee SM, Lim HS, et al. A Study on the operational definition of disease based on national health insurance claim data. 2017 NHIS Ilsan hospital institute health insurance & clinical research. 2017 Dec. 88p. Report No.: 2017-20-029. 

18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-83. 

    상세보기

19. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43(11):1130-9. 

    상세보기

20. Kim J, Hahm MI, Park EC, et al. Economic burden of cancer in South Korea for the year 2005. J Prev Med Public Health 2009;42(3):190-8. 

    원문보기 상세보기

21. Kim JH. 2018 Korean Liver Cancer Association and National Cancer Center for Clinical Practice Guidelines of Hepatocellular Carcinoma: What's Different from 2014? Korean J Gastroenterol 2019;74(2):101-9. 

    상세보기

22. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009;50(1):89-99. 

    상세보기

23. White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol 2012; 10(5):547-54. 

    상세보기

24. Nguang SH, Wu CK, Liang CM, et al. Treatment and cost of hepatocellular carcinoma: A population-based cohort study in Taiwan. Int J Environ Res Public Health 2018;15(12):2655. 

    상세보기

25. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35(9):2155-66. 

    상세보기

26. Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 2014;37(2): 438-44. 

    상세보기

27. Hong YM, Yoon KT, Cho M, et al. Trends and patterns of hepatocellular carcinoma treatment in Korea. J Korean Med Sci 2016;31(3):403-9. 

    상세보기

28. Kwon JW, Shin S, Lee JH, et al. The Impact of the national Liver Cancer Surveillnace Program on the Early Detection, Mortality and Medical cost. National Evidence-based Healthcare Collaboraing Agency 2016. Available from https://www.neca.re.kr/lay1/program/S1T11C145/report/view.do?seq234. Accessed March 21, 2021. 

29. Kim Y, Shin S, Park J, et al. Costing methods in Healthcare. Available from https://www.neca.re.kr/lay1/bbs/S1T11C102/F/39/view.do?article_seq5332&cpage1&rows10&condition&keyword&show&cat. Accessed March 21, 2021. 

저자의 다른 논문 :

이의경 (28)